To bring key stakeholders (HCPs, pharmaceutical and biotech companies, associations and advocacy groups) together for the common purpose of providing accurate and relevant information to the broader oncology community about the importance of testing and biomarker identification, and how to utilize biomarker status to inform treatment decisions.
To emphasize the importance of biomarker testing, comprehensive genomic profiling, and identification of actionable targets across disease states.
To improve:
Learn about the importance of biomarker testing in NSCLC.
Download our overview of the established and emerging biomarkers for NSCLC in the United States.
Coming Soon: Biomarker Testing with GI cancers.
Click on each member’s name for more information.
© 2023 MJH Life Sciences®. Content developed independently by OncLive®.